Dr. Margolis is accountable for Brii’s clinical programs of infectious diseases therapy area in US and provides strategic input and support for the clinical programs in China.

Prior to joining the company, Dr. Margolis was Medical Director and Senior Medical Director for both GSK and ViiV Healthcare, serving as the lead physician for the clinical development program for the long-acting integrase inhibitor, cabotegravir. Within this role he created and executed the strategic plan for the clinical development of this first long-acting treatment regimen in HIV, CAB+RPV, inclusive of the clinical collaborations with Janssen Pharmaceuticals, IMPAACT and the ACTG, resulting in worldwide regulatory submissions and the first approval and launch of this novel approach to HIV therapy. David also oversaw the clinical collaboration with the NIH for the evaluation of cabotegravir for the prevention of HIV and has worked across all stages of clinical development from pre-clinical discovery through Phase 3 and post-marketing studies. While at GSK and ViiV, Dr. Margolis maintained a clinical ID practice , serving as an Assistant Consulting Professor in the Infectious Diseases Department of Duke University Medical Center for the prior 8 years, caring for patients with infectious diseases and serving as the lead attending for the ID fellow’s clinic.

Dr. Margolis received his MD from Duke University School of Medicine, concurrent with a Masters of Public Health at the University of North Carolina, Chapel Hill and then completed an Internal Medicine residency at University of Colorado Health Science Center and a fellowship in Infectious Diseases at University of California at San Diego in La Jolla, with a research focus on infectious diseases in the immunocompromised host.